Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor

Eitemau Tebyg

• A phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib
  gan: Yu, Helena A., et al.
  Cyhoeddwyd: (2016)
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  gan: Pao, William, et al.
  Cyhoeddwyd: (2005)
• EGFR exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib
  gan: Naidoo, J, et al.
  Cyhoeddwyd: (2015)
• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  gan: Oxnard, Geoffrey R., et al.
  Cyhoeddwyd: (2011)
• Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design
  gan: Chaft, Jamie E., et al.
  Cyhoeddwyd: (2011)